which glp 1 agonists have cardiovascular benefit and mortality outcomes with GLP-1 receptor vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Frontiers | The benefits of
Description
The approved lanestype 2 diabetes and obesityblurred almost instantly
Some researchers have highlighted post-treatment study findings that have shown that people tend to suffer from a high risk of weight regain after stopping these drugs
doi: 10.3390/biomedicines9040383
Lixisenatide and exenatide are much weaker GLP-1 drugs compared with semaglutide, tirzepatide and several others that are in clinical trials as shown below for weight loss
A study in The New England Journal of Medicine found that just 33% of the dose drove 72% of the weight loss at week 72 with a lower side effect profile
Wegovy produced average body weight reductions of 15 to 17 percent in clinical trials
